Novartis Investigative Site

Northridge, California 91328

0 studies enrolling now · 13 studies all time

What they study most

Acute Heart Failure, Acute Myocardial Infarction, Atherosclerosis, Breast Neoplasms, Cardiovascular Disease and Lipoprotein(a), Cardiovascular Events, Chronic Heart Failure, Diabetes Mellitus and Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure and Reduced Ejection Fraction, Neoplasms, Gastrointestinal Tract, Obesity

Studies at this site

• Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD — Running, not enrolling
• LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib — Completed
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer — Completed
• Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure — Stopped early
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed
• A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People — Stopped early